Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 16.881
Filtrar
1.
Zhongguo Zhen Jiu ; 41(9): 1005-9, 2021 Sep 12.
Artigo em Chinês | MEDLINE | ID: mdl-34491650

RESUMO

OBJECTIVE: To observe the effect of auricular acupuncture on reduction rate of sertraline hydrochloride, and to explore the long-term efficacy of auricular acupuncture in patients with depression. METHODS: Seventy-two patients with depression were randomly divided into an observation group (36 cases, 1 case dropped off) and a control group (36 cases, 2 cases dropped off). The patients in the control group were treated with conventional dosage reduction method, that is, the dosage of sertraline hydrochloride was reduced by 25% every week until the dosage was stopped completely on the premise of no aggravation of depressive symptoms. Based on the conventional dosage reduction method used in the control group, the patients in the observation group were treated with auricular acupuncture at Xin (CO15), Gan (CO12), Shenmen (TF4), Pizhixia (AT4) and Neifenmi (CO18), once every 3 days for 4 weeks. The reduction of dosage was observed before dosage reduction, after 1, 2, 3, 4 weeks of dosage reduction and follow-up 6 months after the end of treatment; the rate of dosage reduction was observed after 4 weeks of dosage reduction and during follow-up; the Hamilton depression scale (HAMD) was used to evaluate the depression severity before dosage reduction, after 4 weeks of dosage reduction and during follow-up; the incidence rate of withdrawal syndrome and clinical efficacy were compared between the two groups. RESULTS: The dosage of sertraline hydrochloride in the observation group was less than that in the control group after 2, 3, 4 weeks of dosage reduction and during follow-up (P<0.05). The dosage reduction rates were 80.6% and 82.2% after 4 weeks of dosage reduction and during follow-up in the observation group, which were higher than 65.8% and 62.2% in the control group (P<0.05). After 4 weeks of dosage reduction, the HAMD scores in the two groups were higher than those before dosage reduction (P<0.05), and the HAMD score in the observation group was lower than that in the control group (P<0.05). During follow-up, HAMD score in the observation group was lower than that in the control group and that after 4 weeks of dosage reduction (P<0.05), while HAMD score in the control group was higher than that before dosage reduction and that after 4 weeks of treatment (P<0.05). The incidence rate of withdrawal syndrome in the observation group was 11.4% (4/35), which was lower than 47.1% (16/34) in the control group (P<0.05). After 4 weeks of dosage reduction and during follow-up, the total effective rate was 97.1% (34/35) in the observation group, which was higher than 79.4% (27/34) in the control group (P<0.05). CONCLUSION: Auricular acupuncture could effectively reduce the dosage of sertraline hydrochloride, improve the dosage reduction rate, reduce the incidence of withdrawal syndrome and reduce the risk of long-term recurrence in patients with depression.


Assuntos
Terapia por Acupuntura , Acupuntura Auricular , Pontos de Acupuntura , Depressão/tratamento farmacológico , Humanos , Sertralina , Resultado do Tratamento
2.
Zhongguo Zhong Yao Za Zhi ; 46(16): 4230-4237, 2021 Aug.
Artigo em Chinês | MEDLINE | ID: mdl-34467737

RESUMO

This study aimed to explore the mechanism of Xiaoyao San(XYS) in the treatment of three diseases of liver depression and spleen deficiency, ie, depression, breast hyperplasia, and functional dyspepsia, and to provide a theoretical basis for the interpretation of the scientific connotation of "treating different diseases with the same method" of traditional Chinese medicines. Traditional Chinese medicine systems pharmacology database and analysis platform(TCMSP) was used to screen the active components of XYS which underwent principal component analysis(PCA) with the available drugs for these three diseases to determine the corresponding biological activities. The targets of XYS on depression, breast hyperplasia, and functional dyspepsia were obtained from GeneCards, TTD, CTD, and DrugBank databases. Cytoscape was used to plot the "individual herbal medicine-active components-potential targets" network. The resulting key targets were subjected to Kyoto encyclopedia of genes and genomes(KEGG) pathway analysis and gene ontology(GO) enrichment analysis. A total of 121 active components of XYS and 38 common targets in the treatment of depression, breast hyperplasia, and functional dyspepsia were collected. The key biological pathways were identified, including advanced glycation and products(AGEs)-receptor for advanced glycation and products(RAGE) signaling pathway in diabetic complications, HIF-1 signaling pathway, and cancer-related pathways. The key targets of XYS in the treatment of depression, breast hyperplasia, and functional dyspepsia included IL6, IL4, and TNF, and the key components were kaempferol, quercetin, aloe-emodin, etc. As revealed by the molecular docking, a strong affinity was observed between the key components and the key targets, which confirmed the results. The therapeutic efficacy of XYS in the treatment of diseases of liver depression and spleen deficiency was presumedly achieved by reducing the inflammatory reactions. The current findings are expected to provide novel research ideas and approaches to classify the scientific connotation of "treating different diseases with the same method" of Chinese medicines, as well as a theoretical basis for understanding the mechanism of XYS and exploring its clinical applications.


Assuntos
Medicamentos de Ervas Chinesas , Dispepsia , Depressão/tratamento farmacológico , Medicamentos de Ervas Chinesas/farmacologia , Dispepsia/tratamento farmacológico , Humanos , Hiperplasia/tratamento farmacológico , Medicina Tradicional Chinesa , Simulação de Acoplamento Molecular
3.
Rev Assoc Med Bras (1992) ; 67(3): 462-467, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-34468615

RESUMO

Dry eye disease (DED) is a multifactorial disease affecting tear quality and/or production and eye surface and is one of the most common eye disorders found in clinical practice. The association between psychiatric disorders and dry eye has been the subject of several studies since patients with this syndrome present a tendency toward a depressive mood. This narrative review aims to demonstrate the relationship between depression and DED, which is due to the side effects of psychotropic drugs or the tendency of the low pain threshold of the depressive patient. The work was produced from the analysis of 13 articles published during the last decade on this subject and demonstrated that the depressive state is linked to the appearance or worsening of DED resulting from chronic eye pain. Also, the treatment of depression with selective inhibitors of serotonin receptors causes inflammatory cytokine secretion with subsequent inflammation and apoptosis of cells on the ocular surface. The need for new studies on optimization of psychiatric treatment in patients with ophthalmic diseases, such as DED, was verified, aiming at the relief of symptoms and the reduction of psychological and eye damage caused by them.


Assuntos
Dor Crônica , Síndromes do Olho Seco , Transtornos Mentais , Depressão/tratamento farmacológico , Síndromes do Olho Seco/tratamento farmacológico , Humanos , Lágrimas
4.
ACS Chem Neurosci ; 12(18): 3387-3396, 2021 09 15.
Artigo em Inglês | MEDLINE | ID: mdl-34469122

RESUMO

Quercitrin (Qc) is a well-known flavonoid compound that exerts anti-inflammation effects on various diseases. The present study aimed to investigate the antidepressant-like response of Qc and its underlying mechanisms concerning neuroinflammation and neuroplasticity in mice with lipopolysaccharide (LPS)-induced depression-like behaviors. The results showed a single dose of Qc (10 mg/kg) produced an antidepressant-like effect at 2 h postadministration and lasted for at least 3 days. The expressions of neuroplasticity signaling molecules of pCREB/BDNF/PSD95/Synapsin1 were upregulated at 2 h, and ERK signaling was upregulated for 3 days in the hippocampus after a single administration of Oc or ketamine. A 5-day treatment of LPS led to depression-like behaviors, including reduced sucrose preference and increased immobility in the tail suspension test or forced swim test, which were all reversed by a single dose of Qc. In LPS-treated mice, Qc reduced the levels of inflammation-related factors including IL-10, IL-1ß, and TNF-α in serum, as well as the activations of PI3K/AKT/NF-κB and MEK/ERK pathways in the hippocampus. Moreover, Qc restored the expressions of pCREB/BDNF/PSD95/Synapsin1 signaling in the hippocampus that were impaired by LPS. LY294002, a PI3K inhibitor, but not PD98059, a MEK inhibitor, produced effects similar to Qc. LY294002 also restored the expressions of pCREB/BDNF/PSD95/Synapsin1 signaling in the hippocampus impaired by LPS. Additionally, subeffective doses of Qc and LY294002 induced behavioral and molecular synergism. Together, the depression-like behaviors in LPS-treated mice were alleviated by a single dose of Qc likely via inhibition of the activations PI3K/AKT/NF-κB inflammation signaling and subsequent improvement of neuroplasticity.


Assuntos
Lipopolissacarídeos , NF-kappa B , Animais , Fator Neurotrófico Derivado do Encéfalo/metabolismo , Depressão/tratamento farmacológico , Hipocampo/metabolismo , Lipopolissacarídeos/toxicidade , Camundongos , NF-kappa B/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Quercetina/análogos & derivados
5.
Ann Intern Med ; 174(8): JC89, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34339230

RESUMO

SOURCE CITATION: Watt JA, Goodarzi Z, Veroniki AA, et al. Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis. BMJ. 2021;372:n532. 33762262.


Assuntos
Demência , Depressão , Demência/terapia , Depressão/tratamento farmacológico , Humanos , Metanálise em Rede
6.
Curr Opin Anaesthesiol ; 34(5): 556-562, 2021 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-34435599

RESUMO

PURPOSE OF REVIEW: The antidepressant effect of subanesthetic doses of ketamine was recognized 20 years ago. This review briefly summarizes the current understanding of the antidepressant mechanisms and the available clinical research on the use of racemic ketamine and enantiomer esketamine for depression. RECENT FINDINGS: The antidepressant effect of subanesthetic doses of ketamine is currently considered to be predominantly mediated by improved neuroplasticity in cortico-limbic areas in the brain. Single dose of 0.5 mg/kg of ketamine infused intravenously over 40 min, or single intranasal dose of esketamine cause rapid antidepressant and antisuicidal effects within hours of administration, and the antidepressant effect may last up to a week. Repeated administration of nasal spray esketamine is considered to prevent relapse of depression. Longitudinal studies are currently insufficient. When used in various doses for anesthetic induction for electroconvulsive therapy, ketamine improves seizure quality and may possibly diminish posttherapy cognitive impairment. SUMMARY: A rapid onset antidepressive effect of ketamine and esketamine has been proven conclusively. The results of extensive basic science research of the mechanism of action of low-dose ketamine doses has led to an alternative hypothesis of the pathophysiology of depression and the development of a novel neurotrophic concept of depression. Further longitudinal studies are warranted to determine the safety and efficacy of repeated administration of ketamine and its analogs to prevent relapse and recurrence of depression.


Assuntos
Eletroconvulsoterapia , Ketamina , Administração Intranasal , Antidepressivos/uso terapêutico , Depressão/tratamento farmacológico , Humanos
7.
Lancet Psychiatry ; 8(9): 824-835, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-34419187

RESUMO

The use of SSRIs for the treatment of depression and anxiety in young people is increasing. However, the effects of SSRIs in adolescence, a time when there are substantial changes in neural, cognitive, and social functioning, are not well understood. Here, we review evidence from clinical trials about the benefits and risks of SSRIs in young people and consider their mechanisms of action, as shown through human experimental work and animal models. We emphasise key outstanding questions about the effects of SSRIs in youth, identified through gaps in the literature and in consultation with young people with lived experience. It is crucial to characterise the mechanisms underpinning risks and benefits of SSRIs in this age group to progress the field, and to narrow the chasm between the widespread use of SSRIs in youth and the science on which this use is based.


Assuntos
Ansiolíticos/uso terapêutico , Antidepressivos/uso terapêutico , Ansiedade/tratamento farmacológico , Depressão/tratamento farmacológico , Inibidores de Captação de Serotonina/uso terapêutico , Adolescente , Animais , Ansiolíticos/farmacologia , Antidepressivos/farmacologia , Humanos , Inibidores de Captação de Serotonina/farmacologia , Resultado do Tratamento
8.
Zh Nevrol Psikhiatr Im S S Korsakova ; 121(5. Vyp. 2): 91-98, 2021.
Artigo em Russo | MEDLINE | ID: mdl-34405663

RESUMO

The review presents information on the most effective current non-drug methods of treatment of depression used in practice. A review of publications in PubMed and PsycINFO and Cochrane Library over the past 10 years was conducted. Non-drug biological therapies demonstrate high efficacy in the reduction of depressive symptoms in patients with recurrent depressive disorder. The use of non-drug therapy does not preclude the continuation of pharmacological therapy. In order to choose an optimal method of treatment, the psychophysical state of a patient, severity of depressive symptoms, response to drug therapy, and possibility of prescribing pharmacological therapy should be taken into account, and the principles of evidence-based medicine should be taken into consideration when making a decision.


Assuntos
Depressão , Estimulação Magnética Transcraniana , Depressão/tratamento farmacológico , Humanos , Resultado do Tratamento
9.
Zh Nevrol Psikhiatr Im S S Korsakova ; 121(5. Vyp. 2): 106-112, 2021.
Artigo em Russo | MEDLINE | ID: mdl-34405665

RESUMO

A review of works devoted to the problem of psychopharmacotherapy of depression in general medical practice is presented. The issues of its comorbidity with somatic and neurological diseases, as well as multimorbidity are discussed. Both direct and side-effects of antidepressants, which are important for effective therapy of not only affective disorders proper, but also the symptoms of the leading pathology, are considered in detail for individual organs and systems. The analysis of the preferred pharmacological classes of antidepressants, which are drugs of first choice, taking into account the somatic condition of the patient, is carried out, and drugs are indicated, the appointment of which is undesirable for the treatment of a patient with a certain disease. The presented results are aimed both at increasing the efficiency of therapy for patients with general medical level of health care, and at increasing the safety of treatment of psychiatric patients with concomitant somatic disorders.


Assuntos
Antidepressivos , Depressão , Antidepressivos/efeitos adversos , Comorbidade , Depressão/tratamento farmacológico , Humanos
10.
Zh Nevrol Psikhiatr Im S S Korsakova ; 121(5. Vyp. 2): 116-121, 2021.
Artigo em Russo | MEDLINE | ID: mdl-34405667

RESUMO

Based on a clinical case, the authors consider the problem of the optimal choice of an antidepressant, taking into account not only the psychopathological structure of depression, the severity and characteristics of its triad, but also the presence of somatic symptoms. This determines the need for a comprehensive analysis of the pharmacological profile of prescribed antidepressants, their psychotropic and somatotropic effects. The switch of the patient to brintellix, which has polymodal neuroreceptor activity, at a dose of 20 mg per day, made it possible to achieve remission and reduce adverse reactions caused by SSRIs.


Assuntos
Antidepressivos , Depressão , Antidepressivos/uso terapêutico , Depressão/tratamento farmacológico , Humanos , Inibidores de Captação de Serotonina/uso terapêutico
11.
Brain Behav ; 11(8): e2300, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34333865

RESUMO

In this study, the antidepression effects of genistein were investigated in rats induced with chronic mild stress. Animals were designated into the following groups: normal control, control, 10 mg, and 100 mg. The dose was given for 45 consecutive days via the oral route. Sucrose preference analysis, forced swim, and open field tests were performed, and serum cortisol and monoamine levels in brain tissue were determined. The mRNA and protein expression of brain-derived neurotrophic factor (BDNF) was also examined. Supplementation with genistein significantly increased the sucrose preference ratio, locomotor activity, and monoamines and decreased serum cortisol levels. The mRNA expression of BDNF in the brain tissue was substantially reduced by 0.73% in control rats. However, supplementation with genistein significantly increased BDNF mRNA expression (by 107% and 229.6% in groups 10 mg and 100 mg, respectively). Similarly, the protein expression of BDNF increased by 82.3% and 141.2% in groups 10 mg and 100 mg, respectively. Taken together, these results suggest that supplementation with genistein may be effective against depression.


Assuntos
Fator Neurotrófico Derivado do Encéfalo , Depressão , Animais , Antidepressivos/farmacologia , Comportamento Animal , Fator Neurotrófico Derivado do Encéfalo/genética , Fator Neurotrófico Derivado do Encéfalo/metabolismo , Depressão/tratamento farmacológico , Modelos Animais de Doenças , Genisteína/farmacologia , Hipocampo/metabolismo , Ratos , Estresse Psicológico/tratamento farmacológico
14.
18.
Artigo em Russo | MEDLINE | ID: mdl-34460170

RESUMO

A combination of depression and alcohol use disorder (AUD) is a typical and most common example of a dual diagnosis at the intersection of general psychiatry and addiction psychiatry. A comorbidity of depression and AUD is more common than it can be brought about by mere coincidence, which might be explained to some extent by the synergetic effect of both diseases, with each of them complicating the course and worsening the prognosis of the other. Treatment protocols for patients with depression and comorbid AUD include antidepressants, specific medications for alcohol dependence, and psychotherapy. The first-line antidepressants in the treatment of patients with a comorbid combination of depression and alcohol use disorder, as in other clinical situations implying use of antidepressants, are selective serotonin reuptake inhibitors (SSRIs). Fluvoxamine has certain advantages over the other SSRIs in the treatment of patients with a depression and comorbid AUD.


Assuntos
Alcoolismo , Alcoolismo/complicações , Alcoolismo/diagnóstico , Alcoolismo/epidemiologia , Antidepressivos/uso terapêutico , Depressão/diagnóstico , Depressão/tratamento farmacológico , Depressão/epidemiologia , Fluvoxamina , Humanos , Inibidores de Captação de Serotonina/uso terapêutico
19.
Zhongguo Zhong Yao Za Zhi ; 46(14): 3678-3686, 2021 Jul.
Artigo em Chinês | MEDLINE | ID: mdl-34402292

RESUMO

This study aimed to investigate the antidepressant effects of total alkaloids of Fibraurea recisa in HT22 cells damaged by corticosterone (CORT) in vitro and in a mouse model of chronic unpredictable mild stress (CUMS) as well as the underlying mechanisms.In cellular experiments,the viability of CORT-damaged HT22 cells was detected using cell counting kit-8 (CCK-8),and the cell apoptosis was detected by Hoechst 33258 staining.In animal experiments,C57BL/6N mice were randomly divided into the control group,model group,low (100 mg·kg~(-1)),medium (200 mg·kg~(-1)) and high (400 mg·kg~(-1))-dose of total alkaloids of F.recisa groups,and positive control group.After 21 days of CUMS exposure,their depressive behaviors were observed in behavioral and Morris water maze tests.The serum levels of 5-hydroxytryptamine (5-HT),dopamine (DA),and norepinephrine (NE) were assessed by ELISA.The expression levels of apoptosis-related proteins Bcl-2,Bax and cleaved caspase-3 in HT22 cells and mouse hippocampus were detected by Western blot.The results suggested that total alkaloids of F.recisa alleviated the damage of HT22 cells induced by CORT in a dose-dependent manner.The Hoechst 33258 staining uncovered that total alkaloids of F.recisa better reduced the blue spots and inhibited cell apoptosis.The results of animal experiments showed that total alkaloids of F.recisa significantly improved the depression-like behaviors of mice and increased the serum levels of 5-HT,DA and NE as compared with those in the model group.The Western blot assays revealed a significant up-regulation of Bcl-2 protein expression,but an obvious reduction in Bax and cleaved caspase-3protein expression in the total alkaloids of F.recisa group.In conclusion,total alkaloids of F.recisa inhibited depression possibly by regulating the apoptosis-related protein expression or elevating the monoamine neurotransmitter levels in the brain.


Assuntos
Alcaloides , Depressão , Alcaloides/farmacologia , Animais , Antidepressivos/farmacologia , Depressão/tratamento farmacológico , Modelos Animais de Doenças , Hipocampo , Camundongos , Camundongos Endogâmicos C57BL , Estresse Psicológico
20.
Nutrients ; 13(8)2021 Aug 17.
Artigo em Inglês | MEDLINE | ID: mdl-34444980

RESUMO

Recent animal studies have supported that Lactobacillus plantarum PS128 (PS128) can reduce the severity of anxiety and depression. However, previous studies did not focus on the sleep quality and mood of humans. This study determines whether PS128 reduces the severity of anxiety and depressive symptoms, regulates autonomic nervous system function, and improves sleep quality. Forty participants between 20 and 40 years of age with self-reported insomnia were randomly assigned to two groups, a PS128 group and a placebo group, in a double-blind trial. Participants took two capsules of either PS128 or a placebo after dinner for 30 days. Study measures included subjective depressive symptoms, anxiety and sleep questionnaires, and miniature-polysomnography recordings at baseline and on the 15th and 30th days of taking capsules. Overall, all outcomes were comparable between the two groups at baseline and within the 30-day period, yet some differences were still found. Compared to the control group, the PS128 group showed significant decreases in Beck Depression Inventory-II scores, fatigue levels, brainwave activity, and awakenings during the deep sleep stage. Their improved depressive symptoms were related to changes in brain waves and sleep maintenance. These findings suggest that daily administration of PS128 may lead to a decrease in depressive symptoms, fatigue level, cortical excitation, and an improvement in sleep quality during the deep sleep stage. Daily consumption of PS128 as a dietary supplement may improve the depressive symptoms and sleep quality of insomniacs, although further investigation is warranted.


Assuntos
Ansiedade/tratamento farmacológico , Depressão/tratamento farmacológico , Lactobacillus plantarum , Probióticos , Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico , Sono , Adulto , Afeto , Ansiedade/complicações , Ansiedade/microbiologia , Transtornos de Ansiedade/complicações , Transtornos de Ansiedade/tratamento farmacológico , Transtornos de Ansiedade/microbiologia , Ondas Encefálicas , Depressão/complicações , Depressão/microbiologia , Transtorno Depressivo/complicações , Transtorno Depressivo/tratamento farmacológico , Transtorno Depressivo/microbiologia , Método Duplo-Cego , Fadiga , Feminino , Microbioma Gastrointestinal , Humanos , Masculino , Projetos Piloto , Polissonografia , Testes Psicológicos , Autorrelato , Distúrbios do Início e da Manutenção do Sono/complicações , Distúrbios do Início e da Manutenção do Sono/microbiologia , Fases do Sono
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...